皮拉佐胺衍生物T1通过MAPK路径调节抑制肝细胞癌细胞增殖
Yuting Zhang1, Yao Chen2, Huina Lv1
1Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, PR China; Department of Oncology, Anhui Medical University, Hefei, Anhui 230032, PR China.
一种新型化合物T1显示出作为肝癌治疗的巨大潜力. 这种pyrazole amide衍生物有效地抑制癌细胞生长并诱导细胞亡,为肝细胞癌提供了一个有前途的新疗法选择.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 肝细胞癌 (HCC) 仍然是全球癌症相关死亡的主要原因.
- 开发用于HCC的新型,有效的化疗剂至关重要.
研究的目的:
- 设计,合成和评估一种新的pyrazole胺衍生物T1,用于治疗肝癌的治疗潜力.
- 研究T1对肝细胞癌细胞的体外和体内抗癌作用.
主要方法:
- 在体外测定:CCK-8,殖民地形成,穿越井迁移,免疫光和西部涂抹.
- 在体内研究:HuH-7异种移植小鼠模型.
- 分子分析:转录组测序和西部抹杀以阐明作用机制.
主要成果:
- T1对HuH-7和HepG2细胞表现出显著的抗增殖和抗迁移作用,HuH7细胞的IC50为47.7μg/mL.
- T1诱导了亡并调节了MAPK信号通路,影响了与亡相关的蛋白质表达.
- 在体内研究表明,T1在异种移植小鼠模型中抑制瘤生长的有效性相当于sorafenib.
结论:
- 新型pyrazole amide衍生物T1显示出对肝细胞癌的强有力的抗癌活性.
- T1的机制涉及对MAPK途径的调节和诱导亡.
- T1代表了进一步开发为HCC治疗的化疗剂的有希望的候选者.
更多相关视频
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
相关概念视频
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
